Achilles Therapeutics (NASDAQ: ACHL)
$0.84
-0.0241 ( -2.79% ) 27.9K
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Market Data
Open
$0.84
Previous close
$0.86
Volume
27.9K
Market cap
$35.82M
Day range
$0.84 - $0.87
52 week range
$0.74 - $1.76
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Quarterly Reports | 1 | Jun 27, 2024 |
| 6-k | Quarterly Reports | 11 | May 24, 2024 |
| 6-k | Quarterly Reports | 3 | May 17, 2024 |
| 6-k | Quarterly Reports | 5 | May 08, 2024 |
| 20-f | Annual reports | 98 | Apr 04, 2024 |
| 6-k | Quarterly Reports | 5 | Nov 13, 2023 |
| 6-k | Quarterly Reports | 3 | Sep 22, 2023 |
| 6-k | Quarterly Reports | 69 | Aug 04, 2023 |